Product Description
a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02281201)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CSL Behring
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, United Kingdom, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Injuries/wounds Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TAP Study | P3 |
Recruiting |
Injuries/wounds Unspecified |
2026-09-01 |